ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DUKE Duke Capital Limited

33.75
0.25 (0.75%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Duke Capital Limited LSE:DUKE London Ordinary Share GG00BYZSSY63 ORDS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 0.75% 33.75 33.50 34.00 33.75 33.20 33.50 438,574 14:03:37
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Unit Inv Tr, Closed-end Mgmt 31.06M 19.59M 0.0472 7.15 139.17M
Duke Capital Limited is listed in the Unit Inv Tr, Closed-end Mgmt sector of the London Stock Exchange with ticker DUKE. The last closing price for Duke Capital was 33.50p. Over the last year, Duke Capital shares have traded in a share price range of 29.25p to 35.00p.

Duke Capital currently has 415,427,000 shares in issue. The market capitalisation of Duke Capital is £139.17 million. Duke Capital has a price to earnings ratio (PE ratio) of 7.15.

Duke Capital Share Discussion Threads

Showing 1051 to 1074 of 1125 messages
Chat Pages: 45  44  43  42  41  40  39  38  37  36  35  34  Older
DateSubjectAuthorDiscuss
15/3/2024
13:15
Well if IC recommend this, I'm definitely out.

Happy to sell at over 33p today. The shares have done little since Aug 2021, other than fall sharply then fluctuate in the lower 30s for the past 18 months. Waste of time. The recent rise is probably down
to the IC rec as mug punters buy in. At least made a half-decent profit including div, which I wasn't expecting, but I won't be buying DUKE again.

bend1pa
11/3/2024
11:52
Big line gone through
panshanger1
07/3/2024
17:03
Very useful to see the Fairmed exit is likely to generate IRR in the high teens. That was not clear to me from yesterday's RNS.

Fabrikat exit at IRR 36% looks to be their 2nd highest exit IRR - see slide 14 of

metis20
07/3/2024
11:31
Looks like 2 very good exits - surprised no reaction at all to the share price, but think this is back in buying territory after recent weakness.
riverman77
07/3/2024
08:42
Yeah they should just provide standard info on exit - or explain why that is not possible / appropriate. Both RNS look positive though.
melody9999
07/3/2024
08:02
You could always contact them and ask.

NEIL JOHNSON ceo 01481 231 816 or write to him or NIGEL BIRRELL, (CHAIRMAN)

47/48 Piccadilly
1st Floor
London
W1J 0DT

this_is_me
07/3/2024
07:52
36% IRR excellent result for Duke once again
senttothegallows
07/3/2024
07:48
Feeling duped.

Yesterday's announcement was ambiguous and
today's does not give an exit price.

piedro
07/3/2024
07:14
Contrast today's Fabricat announcement with yesterday's announcement and draw your own conclusion.
peter27
06/3/2024
13:53
Given the transparency we normally get I was surprised there was so little information and no comment on IRR.
peter27
06/3/2024
10:55
TIDMDUKE

RNS Number : 7443D

Duke Royalty Limited

01 July 2021

1 July 2021

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")



-- The EUR10 million royalty is a 30-year senior secured financing, with monthly payments commencing immediately in July 2021 on Duke's typical investment terms.

senttothegallows
06/3/2024
09:24
Website says £10m.
peter27
06/3/2024
08:11
invested E10M in Fairmed rpyalty on 010721 and since then Duke has received monthly royalties, plus E1.4M gain on exit
melody9999
06/3/2024
07:23
Successful Exit of Investment in Fairmed Healthcare AG



Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to announce the successful exit of its investment in Fairmed Healthcare AG ("Fairmed"), a Switzerland-based provider of high-quality generic prescription medicines, over-the-counter pharmaceuticals, dermocosmetics and dietary supplements in various EU countries.



Overview



· Headline cash consideration of €11.4 million, providing Duke with additional liquidity for new deployments into its pipeline of long-established, profitable businesses

· Payment of €6.0 million has been received with the balance of €5.4 million to be paid by 31 March 2024

· This represents the seventh exit for Duke, delivering its sixth profitable exit. The exit of Fairmed is at the upper end of the expected rate of return for Duke with no equity participation

· Duke's financing solution enabled Fairmed's management team to retain its minority equity stake, while receiving the capital to support the expansion of its product portfolio

· Duke's investment exit was facilitated by Fairmed's majority owner, Strides Pharma Global Pte Ltd, a fully owned subsidiary of Strides Pharma Science Limited ("Strides"). The prepayment of Duke's investment paves the way for Strides to initiate the next phase of its European strategy, utilising Fairmed to expand and strengthen its presence in the region

senttothegallows
06/3/2024
07:21
Fairmed exit at a small cash loss. Additionally management time and opportunity cost.
peter27
05/3/2024
20:12
Very interesting ramellous.
santos123
04/3/2024
18:01
Duke is nearest example to an annuity share. According to ii.
ramellous
04/3/2024
15:40
Quite a surprise.

"Duke Capital Limited, a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to announce it has increased its equity stake in United Glass Group ("UGG") from 30.0% to 73.8% through a £2.9 million secondary share purchase from existing shareholders."

That is just about a buyout with
money to splash without repayment

piedro
22/2/2024
17:17
Think some of those trades at the end were buys not sells, I know mine was @ 30.6pName amended to Capital, still a good buy with Divi over 9 percent
shepc
16/2/2024
20:34
If anyone would like a free ticket to the Mello event, enter the promo code: Corp100 at the checkout.
gregb
16/2/2024
11:12
Duke Royalty are on the MelloMonday show next week

5:00pm James Ashton, CEO at the Quoted Companies Alliance presents What is the QCA?
5:30pm Company presentation by Poolbeg Pharma
6:00pm Company presentation by Time Finance
6:30pm Trading Update from Duke Royalty
6:50pm BASH Panel with Mark Simpson, Kevin Taylor & Graham Neary

davidosh
12/2/2024
15:13
From Trading statement December 2023

Trading Update

Based on current trading, Duke expects to achieve recurring cash revenue* of GBP6.3 million in Q3 FY24. This represents a 12% increase on Q3 FY23 (GBP5.6 million) and an increase on the prior quarter, Q2 FY24, which saw the Company deliver record recurring cash revenue of GBP6.2 million.

AIMHO
GLA
BTG

btgman
12/2/2024
12:36
I'm getting downvoted, but I haven't heard any counter argument. Why do they keep gaining equity stakes in companies they've lent money to?

Are the companies just giving the equity away?
Do Duke think the underlying businesses are just amazing investment opportunities?

I think the answer is the obvious one: The companies are giving up equity because they're struggling to cover repayment costs to Duke.

34adsaddsa
12/2/2024
09:34
Yes there is, because otherwise it could be obvious they couldn't afford the repayments.
34adsaddsa
Chat Pages: 45  44  43  42  41  40  39  38  37  36  35  34  Older

Your Recent History

Delayed Upgrade Clock